Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxRPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy
/0 Comments/in Preclinical Research/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxResults from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer
/0 Comments/in Clinical Trial, Localized/by MaxNewsletter 2/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! This past week has brought encouraging news on both the clinical and preclinical research fronts. Let’s dive into the newsletter and keep fighting on! As usual, we also have a podcast if you prefer to listen to the newsletter, you […]
A New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential
/0 Comments/in Preclinical Research/by MaxNXP800: A Promising New Drug for Hormone-Resistant Prostate Cancer
/0 Comments/in Preclinical Research/by MaxTags
abiraterone acetate ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide diet docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial survival outcomes T-cell therapy theranostics treatment resistance
Latest Posts
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
- Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025